These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4207759)

  • 21. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
    Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
    Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biosynthesis and regulation of mycolic acids in Mycobacterium tuberculosis--a review].
    Luo H; Pang L; Xie J
    Wei Sheng Wu Xue Bao; 2012 Feb; 52(2):146-51. PubMed ID: 22586991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+.
    Wheeler PR; Anderson PM
    Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):451-7. PubMed ID: 8809032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis.
    Phetsuksiri B; Baulard AR; Cooper AM; Minnikin DE; Douglas JD; Besra GS; Brennan PJ
    Antimicrob Agents Chemother; 1999 May; 43(5):1042-51. PubMed ID: 10223912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The structure and function of the isoniazid target in M. tuberculosis.
    Sacchettini JC; Blanchard JS
    Res Microbiol; 1996; 147(1-2):36-43. PubMed ID: 8761720
    [No Abstract]   [Full Text] [Related]  

  • 26. Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis.
    Garza-González E; Guerrero-Olazarán M; Tijerina-Menchaca R; Viader-Salvadó JM
    J Clin Microbiol; 1997 May; 35(5):1287-9. PubMed ID: 9114429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
    Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
    Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Certain properties of isoniazid inhibition of mycolic acid synthesis in cell-free systems of M. aurum and M. avium.
    Quémard A; Mazères S; Sut A; Lanéelle G; Lacave C
    Biochim Biophys Acta; 1995 Jan; 1254(1):98-104. PubMed ID: 7811753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoniazid uptake and growth inhibition of Mycobacterium tuberculosis in relation to time and concentration of pulsed drug exposures.
    Beggs WH; Jenne JW
    Tubercle; 1969 Dec; 50(4):377-85. PubMed ID: 4983736
    [No Abstract]   [Full Text] [Related]  

  • 30. [The mycolic acids analysis with HPLC technique in drug susceptibility testing of Mycobacterium tuberculosis strains].
    Walkiewicz R; Grubek-Jaworska H; Chazan R
    Pneumonol Alergol Pol; 2006; 74(1):89-94. PubMed ID: 17175985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
    Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
    Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro effect of ursolic acid on the inhibition of Mycobacterium tuberculosis and its cell wall mycolic acid.
    Jyoti MA; Zerin T; Kim TH; Hwang TS; Jang WS; Nam KW; Song HY
    Pulm Pharmacol Ther; 2015 Aug; 33():17-24. PubMed ID: 26021818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis.
    Parrish NM; Houston T; Jones PB; Townsend C; Dick JD
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1143-50. PubMed ID: 11257028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.
    Raghunandanan S; Jose L; Kumar RA
    J Antibiot (Tokyo); 2018 Nov; 71(11):939-949. PubMed ID: 30185901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation, characterization, and function of 6-mycolyl-6'-acetyltrehalose in the H37Ra strain of Myocobacterium tuberculosis.
    Takayama K; Armstrong EL
    Biochemistry; 1976 Jan; 15(2):441-7. PubMed ID: 813763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unveiling a tuberculosis drug target.
    Travis J
    Science; 1994 Jan; 263(5144):172. PubMed ID: 8284668
    [No Abstract]   [Full Text] [Related]  

  • 37. Isonicotinic acid hydrazide induced changes and inhibition in mycolic acid synthesis in Nocardia and related taxa.
    Tomiyasu I; Yano I
    Arch Microbiol; 1984 Apr; 137(4):316-23. PubMed ID: 6428369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis.
    Belardinelli JM; Morbidoni HR
    Expert Rev Anti Infect Ther; 2013 Apr; 11(4):429-40. PubMed ID: 23566152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between nicotinamide adenine dinucleotide concentration and antibacterial activity of isoniazid in Mycobacterium tuberculosis.
    Jackett PS; Aber VR; Mitchison DA
    Am Rev Respir Dis; 1977 Apr; 115(4):601-7. PubMed ID: 192114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
    Mdluli K; Slayden RA; Zhu Y; Ramaswamy S; Pan X; Mead D; Crane DD; Musser JM; Barry CE
    Science; 1998 Jun; 280(5369):1607-10. PubMed ID: 9616124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.